



Follicular Lymphoma and high-grade B-Cell Lymphoma

Learn how we successfully supported a large pharmaceutical company by rapidly collecting data for the HTA process of a hematology product.



For an HTA process, we collected long-term follow-up data (>900 pts. up to 12 yrs.) in only 5 months

Situation & challenges

- » The client's aim was to collect data supporting the HTA process and launch of a new drug in the relapsed/refractory setting
- » Follow-up data of patients with lymphoid neoplasms require long observation periods and high case numbers, thus few prospective data are available on patients with FL and DLBCL in higher treatment lines
- » The Tumor Registry Lymphatic Neoplasms (TLN) was launched in 2009 and has followed more than 3,750 patients, initially for 5 years.

Our approach

- » Extension of TLN database, in two cohorts:
 1. Long-term follow-up of all patients with FL or DLBCL from the Tumor Registry Lymphatic Neoplasms (up to 12 years)
 2. Recruiting new patients with FL or DLBCL who start or have started their 3rd-line treatment between index date and data collection
- » Activation of our large and dedicated investigator network
- » Matching of populations to published trial data by MAIC analysis

Results

- iOMEDICO delivered high-quality real world evidence for the client's HTA process on time
- With the TLN Registry we accelerated patient recruitment and generated long-term follow-up (up to 12 years) of specific hematological cohorts
- These real world data (RWD) were used as the external comparator of a pivotal study
- The project closed the gap between clinical trials and routine practice

Project scope



Study type
Registry



5 months
time frame



150 sites
in Germany



> 900
patients



iOMEDICO has conducted various clinical projects, including clinical trials, non-interventional studies and tumor registries in the field of lymphoid neoplasms. Currently, we have fourteen ongoing hematologic projects. Across all entities, our real world database contains more than 82.157 patient datasets from over 500 hospitals, medical practices, and comprehensive cancer centers. We have extensive, high-quality tumor registries for breast cancer, lung cancer, colorectal cancer and numerous other entities.

Interested in working with us?

Get in Touch

Contact us

E: info@iomedico.com

W: www.iomedico.com



Together, we improve oncology

At iOMEDICO, we are experts and specialists in oncology and hematology clinical research. With 30 years of experience and the power of our high-performance oncology network, we accelerate clinical trials, to bring new drugs and treatments to patients faster.

We conduct phase I-IV clinical trials as well as prospective tumor registries. With our large real world database, we provide comprehensive insights for planning drug development and science-driven trial design based on deep understanding of current patient care landscape. The platform links clinical data with translational analytics and patient reported outcome (PRO), to answer the complex questions of precision oncology – even for rare diseases.

IMPROVE
ONCOLOGY